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LETTER TO THE EDITOR
Hyperpolarized 3He MRI Ventilatory Apparent
Diffusion Coefficient of Alpha-1 Antitrypsin Deficiency
Andrew Westcott,1 Dante P.I. Capaldi,1 Alexei Ouriadov,1
Andrew Westcott,2 Dante P.I. Capaldi,2
David G. McCormack,3 and Grace Parraga1,2
To the Editor:
Alpha-1 antitrypsin deficiency (AATD) leads to disabling chronic
obstructive pulmonary disease (COPD). Current therapy aimed at
slowing lung disease progression includes exogenous alpha-1 anti-
trypsin augmentation therapy, but there are few potential new
treatments under development. Currently used measurements of
AATD-related emphysema include the forced expiratory volume in
1 second (FEV1) and the diffusing capacity of carbon monoxide
(DLCO); both are relatively insensitive to therapy,
1 although com-
puted tomography (CT) lung density measurements have been
shown to worsen more slowly in treated patients.2
Hyperpolarized magnetic resonance imaging (MRI) has
emerged as a possible alternative or complementary method for evalu-
ating lung microstructure and function.3 Longitudinal worsening of
MRI ventilation-defect-percent (VDP) was shown to be related to
symptoms and exercise capacity in COPD patients in whom FEV1 was
not predictive.4 The apparent diffusion coefficient (ADC) measured
using 3He and 129Xe MRI has also been demonstrated in patients with
AATD.5 Although 3He MRI ADC is highly reproducible,6 these values
only report from well-ventilated lung, which is important because as
AATD emphysema worsens over time, no inhaled gas MRI informa-
tion can be gleaned from unventilated lung regions.
Our goal was to develop a new biomarker of AATD emphysema
that incorporates functional and microstructural abnormalities that
would be sensitive to disease changes over time. We evaluated a single
patient with a clinical diagnosis of AATD, who provided written
informed consent to study protocols (registered at clinicaltrials.gov as
NCT02279329 and NCT02723474), approved by a local Research
Ethics Board and federal regulatory agency. He was evaluated using spi-
rometry, plethysmography according to guidelines7 and MRI at each
visit; he also completed the St. George Respiratory Questionnaire
(SGRQ), 6-minute walk test (6MWT) and thoracic CT on a 64-slice
Lightspeed VCT scanner (General Electric Healthcare, Milwaukee,
WI) (643 0.625mm, 120 kVp, 100 effective mA, tube rotation time-
5 500 msec, and pitch5 1.0) in breath-hold after inhalation of a 1-L
N2 bag from FRC on visits 2, 4, and 6. The total effective dose was 1.8
mSv (Health Protection Agency of the United Kingdom, NRPB-
SR250). MRI was performed on a 3T system (MR750 Discovery, GE
HealthCare) as previously described6 with diffusion-weighted data
acquired using a multislice interleaved 2D gradient echo diffusion-
weighted sequence for seven 30-mm coronal slices (900 ls selective
radio frequency pulse, flip angle h5 48, echo time5 3.9 msec, repeti-
tion time5 5.6 msec, bandwidth5 62.5 kHz, in-plane reso-
lution5 3.125 3 3.125mm2, b5 0, 1.6 s/cm2); the diffusion-
sensitization gradient pulse ramp up-down time5 500 ls and diffu-
sion time5 1460 ls.
The relative area of the CT density-histogram with values< –950
Hounsfield Units (HU) (RA950) and MRI ventilation-defect-percent
(VDP) were measured using custom-built (MatLab R2014b; Math-
Works, Natick, MA) software.8 ADC maps were generated using 3He
diffusion-weighted images as previously described.9 To determine
regional information, the apical region was segmented from the basal
region based on the location of the carina.
It was previously shown in patients with severe COPD that
ventilation defects spatially and quantitatively correlated with
emphysematous bullae,10 which reinforces the notion that lung
regions with severe emphysema have long time-constants for filling
and cannot be ventilated during a short breath-hold scan. To
account for this, we considered the diffusing capacity of the lung
for carbon monoxide (DLCO) normalized to the ventilated alveolar
volume, which generates KCO, as shown in Eq. 1:
KCO5
DLCO
VA
(1)
where VA is the alveolar volume, or the “accessible” volume avail-
able for gas exchange. In a similar manner, we proposed to normal-
ize ADC in relation to ventilation, which we term the ventilatory
ADC (vADC) as:
vADC5
ADC
12 VDP100
(2)
We prospectively evaluated a single AATD patient who attended
six visits over a 65-month period and received augmentation ther-
apy for the duration of the study, except for a few months between
visit 3 and visit 4. At the first visit, where quality of life measure-
ments were recorded, the 6MWD was normal. As shown in Fig.
F11A, measurements were evaluated using linear regression with time
as the independent variable to calculate slope, r2, and P-value. 3He
MRI ventilation and ADC maps show there was qualitative,
visually-obvious evidence of increasing ADC values in the apical
lung regions and enlarged ventilation defects in the basal lung
regions. In Fig. 1A,C, FEV1 (slope5 –1.8, r
25 0.94, P5 0.001),
RA950 (slope5 0.86, r
25 1, P5 0.02), vADC (slope5 0.03,
r25 0.77, P5 0.02), and VDP (slope5 2.7, r25 0.79, P5 0.02)
significantly changed over time (significant nonzero slope). How-
ever, DLCO (P5 0.70), ADC (P5 0.20), and FEV1/FVC
(P5 0.05) did not significantly change. These results, along with
other important measures, are reflected in the quantitative results
shown in Fig. 1B.
In this proof of concept demonstration, it is important to
note that vADC was generated and used based on the assumption
that in patients with advanced COPD, ventilation defects are dom-
inated by emphysematous bullae and not airways disease.10 This is
certainly also the case in AATD patients where emphysematous
destruction dominates. However, in patients with mild COPD,
ventilation defects also derive from gas trapping due to small-
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airways disease10 and for these patients, different weightings of the
ratio of ADC and VDP should be generated and tested. In this
specific AATD patient with GOLD grade 2 COPD and severe
emphysema, vADC, and VDP as well as apical ADC, RA950,
6MWD, and FEV1 significantly changed over the 65-month fol-
low-up period. Somewhat surprisingly, this was not the case for
DLCO, perhaps because it can be highly variable over time.
We also observed that vADC significantly increased in both
apical and basal regions, whereas VDP did not significantly change in
the apical regions and ADC did not significantly change in the basal
lung regions. These findings are certainly consistent with previous
longitudinal MRI results in COPD patients in whom worsening
emphysematous bullae resulted in larger ventilation abnormalities as
disease progressed. We acknowledge that vADC has not been widely
tested yet and a large-scale study is required in patients with severe
emphysema that includes both KCO and patient outcomes. Neverthe-
less, this preliminary study in a single AATD patient showed that
vADC significantly changed while ADC did not. Moreover, vADC
changes were concordant with significantly worse 6MWD and CT
measurements, which supports its use as a biomarker of airspace
enlargement in patients with severe emphysema.
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